Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunosuppressant
|
| gptkbp:administeredBy |
oral
topical intravenous |
| gptkbp:alsoKnownAs |
gptkb:tacrolimus
|
| gptkbp:approvedBy |
gptkb:FDA
liver transplant kidney transplant heart transplant |
| gptkbp:ATCCode |
L04AD02
|
| gptkbp:brand |
gptkb:Prograf
gptkb:Advagraf gptkb:Astagraf_XL |
| gptkbp:CASNumber |
104987-11-3
|
| gptkbp:discoveredBy |
Fujisawa Pharmaceutical Company
|
| gptkbp:discoveredIn |
1987
|
| gptkbp:foundIn |
gptkb:Streptomyces_tsukubaensis
|
| gptkbp:hasMolecularFormula |
C44H69NO12
|
| https://www.w3.org/2000/01/rdf-schema#label |
FK506
|
| gptkbp:inhibitedBy |
T-lymphocyte activation
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
immunosuppressant
|
| gptkbp:metabolism |
gptkb:CYP3A4
liver |
| gptkbp:sideEffect |
hypertension
nephrotoxicity neurotoxicity hyperglycemia |
| gptkbp:usedFor |
prevention of organ transplant rejection
treatment of autoimmune diseases |
| gptkbp:bfsParent |
gptkb:Streptomyces_species
gptkb:tacrolimus |
| gptkbp:bfsLayer |
6
|